中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2010年
3期
16-18
,共3页
子宫内膜异位症%米非司酮%孕三烯酮%腹腔镜检查
子宮內膜異位癥%米非司酮%孕三烯酮%腹腔鏡檢查
자궁내막이위증%미비사동%잉삼희동%복강경검사
Endometriosis%Mffepristone%Gestrinone%Laparoscopy
目的 探讨米非司酮治疗腹腔镜手术后子宫内膜异位症的临床疗效.方法 将143例腹腔镜保守性手术后子宫内膜异位症患者按照机械抽样法随机分为两组:米非司酮组78例,服用米非司酮10 mg/d,1次/d,连续用3个月;孕三烯酮组65例,服用孕三烯酮2.5 mg,2次/周,连续用3个月;所有患者随访1～2年.比较两种药物治疗子宫内膜异位症的疗效、不良反应情况及对肝功能的影响.结果 两组患者停药后3、6、12个月症状及体征与治疗前比较均明显改善(P<0.01).米非司酮组完全缓解率为85.9%(67/78),孕三烯酮组为84.6%(55/65),两组比较差异无统计学意义(P>0.05).米非司酮组痤疮、体重增加、关节酸痛、转氨酶升高的发生率低于孕三烯酮组(P<0.01或<0.05).米非司酮组停药后排卵、月经恢复时间[(12.0±2.9)、(26.8±3.9)d]均短于孕三烯酮组[(25.3±3.7)、(35.0±4.1)d](P<0.05).结论 米非司酮用于子宫内膜异位症腹腔镜手术后巩固治疗,安全、有效,且不良反应小.
目的 探討米非司酮治療腹腔鏡手術後子宮內膜異位癥的臨床療效.方法 將143例腹腔鏡保守性手術後子宮內膜異位癥患者按照機械抽樣法隨機分為兩組:米非司酮組78例,服用米非司酮10 mg/d,1次/d,連續用3箇月;孕三烯酮組65例,服用孕三烯酮2.5 mg,2次/週,連續用3箇月;所有患者隨訪1～2年.比較兩種藥物治療子宮內膜異位癥的療效、不良反應情況及對肝功能的影響.結果 兩組患者停藥後3、6、12箇月癥狀及體徵與治療前比較均明顯改善(P<0.01).米非司酮組完全緩解率為85.9%(67/78),孕三烯酮組為84.6%(55/65),兩組比較差異無統計學意義(P>0.05).米非司酮組痤瘡、體重增加、關節痠痛、轉氨酶升高的髮生率低于孕三烯酮組(P<0.01或<0.05).米非司酮組停藥後排卵、月經恢複時間[(12.0±2.9)、(26.8±3.9)d]均短于孕三烯酮組[(25.3±3.7)、(35.0±4.1)d](P<0.05).結論 米非司酮用于子宮內膜異位癥腹腔鏡手術後鞏固治療,安全、有效,且不良反應小.
목적 탐토미비사동치료복강경수술후자궁내막이위증적림상료효.방법 장143례복강경보수성수술후자궁내막이위증환자안조궤계추양법수궤분위량조:미비사동조78례,복용미비사동10 mg/d,1차/d,련속용3개월;잉삼희동조65례,복용잉삼희동2.5 mg,2차/주,련속용3개월;소유환자수방1～2년.비교량충약물치료자궁내막이위증적료효、불량반응정황급대간공능적영향.결과 량조환자정약후3、6、12개월증상급체정여치료전비교균명현개선(P<0.01).미비사동조완전완해솔위85.9%(67/78),잉삼희동조위84.6%(55/65),량조비교차이무통계학의의(P>0.05).미비사동조좌창、체중증가、관절산통、전안매승고적발생솔저우잉삼희동조(P<0.01혹<0.05).미비사동조정약후배란、월경회복시간[(12.0±2.9)、(26.8±3.9)d]균단우잉삼희동조[(25.3±3.7)、(35.0±4.1)d](P<0.05).결론 미비사동용우자궁내막이위증복강경수술후공고치료,안전、유효,차불량반응소.
Objective To investigate the role of mifepristone in endometriosis after laparoscopic surgery. Methods One hundred and forty-three women diagnosed with endometriosis after laparoscopic surgery were divided into two groups: one group with 78 cases were given mifepristone at 10 mg once daily (mifepristone group),and the other group with 65 cases were given gestrinone at 2.5 mg,twice every week (gestrinone group). All patients were followed-up 1 to 2 years and observed curative effect, compared the therapy effect on endometriosis as well as the side effects of two drugs. Results The clinical symptom and sign were improved at 3, 6, 12 months in two groups (P< 0.01). The rate of efficiency was 85.9%(67/78) in mifepristone group,and 84.6%(55/65) in gestrinone group, there was no significant difference between two groups (P > 0.05). The rates of acne, weight gain, joint ache, aminotransferase increase was lower in mifepristone group than those in gestrinone group (P <0.01 or <0.05). The recovery time of ovulation or menstruation was shorter in mifepristone group [(12.0 ± 2.9), (26.8 ± 3.9) d]than those in gestrinone group [(25.3 ±3.7), (35.0±4.1) d](P<0.05). Conclusions Mifepristone seems to be an effective,safe,and convenient treatment for endometriosis with low-cost and few side effects. Therefore,it can be used as first choice for treatment of endometriosis after laparoscopic surgery.
